<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467974</url>
  </required_header>
  <id_info>
    <org_study_id>HCC017</org_study_id>
    <nct_id>NCT00467974</nct_id>
  </id_info>
  <brief_title>Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma</brief_title>
  <official_title>A Randomized Controlled Trial of Transarterial Ethanol Ablation (TEA) With Lipiodol-Ethanol Mixture (LEM) Versus Transcatheter Arterial Chemoembolisation (TACE) for Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety&#xD;
      and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard loco-regional treatment for unresectable hepatocellular carcinoma is&#xD;
      transarterial chemoembolization (TACE). However, The drawback of conventional&#xD;
      chemoembolization (TACE) for liver cancer is that it cannot effectively embolize portal&#xD;
      venules supplying the tumors, therefore chemoembolization is difficult to completely&#xD;
      eradicate the tumor. Usually multiple treatments are required and tumor recurrences are&#xD;
      common.&#xD;
&#xD;
      Transarterial Ethanol Ablation (LEM) can potentially provide a better treatment outcome with&#xD;
      fewer treatment sessions. Preliminary results from a clinical study showed that the&#xD;
      complication rate is reduced while survival rate may be improved. This study aims to compare&#xD;
      survival duration and response rate between the treatments TACE and LEM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor response</measure>
    <time_frame>4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of conversion to resectable stage</measure>
    <time_frame>4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity of treatment</measure>
    <time_frame>4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to one year after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>consumption of hospital resources</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEA with LEM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TEA with LEM</intervention_name>
    <description>Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Transarterial chemoembolisation (TACE)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient factor&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Child-Pugh A or B cirrhosis&#xD;
&#xD;
          -  ECOG performance status Grade 2 or below&#xD;
&#xD;
          -  No serious concurrent medical illness&#xD;
&#xD;
          -  No prior treatment (including surgery) for HCC&#xD;
&#xD;
        Tumor factor&#xD;
&#xD;
          -  Histologically or cytologically proven HCC (an alphafetoprotein level &gt; 500 ug/ml in&#xD;
             the presence of radiological findings suggestive of HCC in a patient with chronic HBV&#xD;
             or HCV infection can be considered eligible at investigator's discretion)&#xD;
&#xD;
          -  Unresectable and locally advanced disease without extra-hepatic disease&#xD;
&#xD;
          -  Massive expansive or nodular tumor morphology with measurable lesion on CT&#xD;
&#xD;
          -  Size of largest tumor &lt;= 15cm in largest dimension&#xD;
&#xD;
          -  Number of main tumor &lt;= 5, excluding associated small satellite lesions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient factor&#xD;
&#xD;
          -  History of prior malignancy except skin cancer&#xD;
&#xD;
          -  History of significant concurrent medical illness such as ischemic heart disease or&#xD;
             heart failure&#xD;
&#xD;
          -  History of acute tumor rupture&#xD;
&#xD;
          -  Serum creatinine level &gt; 180 umol/L&#xD;
&#xD;
          -  Presence of biliary obstruction not amenable to percutaneous drainage&#xD;
&#xD;
          -  Child-Pugh C cirrhosis&#xD;
&#xD;
        Evidence of poor liver function&#xD;
&#xD;
          -  History of hepatic encephalopathy, or&#xD;
&#xD;
          -  Intractable ascites not controllable by medical therapy, or&#xD;
&#xD;
          -  History of variceal bleeding within last 3 months, or&#xD;
&#xD;
          -  Serum total bilirubin level &gt; 50 umol/L, or&#xD;
&#xD;
          -  Serum albumin level &lt; 28g/L, or&#xD;
&#xD;
          -  INR &gt; 1.3&#xD;
&#xD;
        Tumor factor&#xD;
&#xD;
          -  Presence of extrahepatic metastasis&#xD;
&#xD;
          -  Predominantly infiltrative lesion&#xD;
&#xD;
          -  Diffuse tumor morphology with extensive lesions involving both lobes.&#xD;
&#xD;
        Vascular complications&#xD;
&#xD;
          -  Hepatic artery thrombosis, or&#xD;
&#xD;
          -  Partial or complete thrombosis of the main portal vein, or&#xD;
&#xD;
          -  Tumor invasion of portal branch of contralateral lobe, or&#xD;
&#xD;
          -  Hepatic vein tumor thrombus, or&#xD;
&#xD;
          -  Significant arterioportal shunt not amenable to shunt blockage, or&#xD;
&#xD;
          -  Significant arteriovenous shunt not amenable to shunt blockage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon CH Yu, MD, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Diagnostic Radiology and Organ Imaging, Prince of Wales Hospital, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Diagnostic Radiology and Organ Imaging, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>April 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2007</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Edwin P Hui</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

